Company news

DBV Technologies SA news in 2026

DBV Technologies SA's news releases, calls and decks from 2026, newest first.

View company

DBV Technologies to Report Third Quarter 2026 Financial Results and Business Update on October 28, 2026

October 27, 2026

DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years

September 29, 2026

DBV Technologies annonce le dépôt de sa demande de licence biologique (BLA) auprès de la Food and Drug Administration des Etats-Unis pour le patch VIASKIN® Peanut destiné aux enfants âgés de 4 à 7 ans.

September 29, 2026

DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years

September 29, 2026

DBV Technologies to Participate in Upcoming September Investor Conferences

September 3, 2026

DBV Technologies annonce sa participation à plusieurs conférences investisseurs en septembre

September 2, 2026

Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 août 2026

September 1, 2026

DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq

July 29, 2026

DBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Sales

July 17, 2026

DBV Technologies Announces the Filing of its 2026 Half-Year Report ― Conditions for Accessing or Consulting the Report

July 16, 2026

DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update

July 16, 2026

DBV Technologies to Report Second Quarter 2026 Financial Results and Business Update on July 16, 2026

July 14, 2026

DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for Filing

June 29, 2026

DBV Technologies Announces Inclusion in the Euronext Tech Leaders Index

June 23, 2026

DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference

June 9, 2026

DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026

June 8, 2026

DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

June 5, 2026

DBV Technologies Announces the Results of its 2026 Combined General Meeting

June 3, 2026

DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy

June 2, 2026

DBV Technologies to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq

May 12, 2026

DBV Technologies Reports First Quarter 2026 Financial Results

April 30, 2026

DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document

March 26, 2026

DBV Technologies Reports Full Year 2025 Financial Results and Business Update

March 26, 2026

DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review

March 24, 2026

DBV Technologies to Participate in Upcoming March Investor Conferences

March 4, 2026

DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting

February 28, 2026

DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting

February 10, 2026

DBV Technologies to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit

February 9, 2026

DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing

January 16, 2026

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

January 7, 2026

Calls in 2026

Decks in 2026